Addition of aprepitant improves acute emesis control in children and adolescents receiving induction...
Addition of aprepitant improves acute emesis control in children and adolescents receiving induction chemotherapy for acute myeloid leukaemia: a randomised, open-label trial
About this item
Full title
Author / Creator
Publisher
London: British Medical Journal Publishing Group
Journal title
Language
English
Formats
Publication information
Publisher
London: British Medical Journal Publishing Group
Subjects
More information
Scope and Contents
Contents
ObjectivesMore than 50% patients develop emesis during induction therapy for acute myeloid leukaemia (AML). The addition of aprepitant for emesis control in children receiving induction for AML have not been explored.MethodsA single-institutional randomised, open-label trial (NCT02979548) was conducted where children between 5 and 18 years with the...
Alternative Titles
Full title
Addition of aprepitant improves acute emesis control in children and adolescents receiving induction chemotherapy for acute myeloid leukaemia: a randomised, open-label trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2456413162
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2456413162
Other Identifiers
ISSN
2045-435X
E-ISSN
2045-4368
DOI
10.1136/bmjspcare-2020-002595
